267 related articles for article (PubMed ID: 30084834)
1. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Chen GM; Kannan L; Geistlinger L; Kofia V; Safikhani Z; Gendoo DMA; Parmigiani G; Birrer M; Haibe-Kains B; Waldron L
Clin Cancer Res; 2018 Oct; 24(20):5037-5047. PubMed ID: 30084834
[No Abstract] [Full Text] [Related]
2. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
3. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
4. Creation and validation of models to predict response to primary treatment in serous ovarian cancer.
Gonzalez Bosquet J; Devor EJ; Newtson AM; Smith BJ; Bender DP; Goodheart MJ; McDonald ME; Braun TA; Thiel KW; Leslie KK
Sci Rep; 2021 Mar; 11(1):5957. PubMed ID: 33727600
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
[No Abstract] [Full Text] [Related]
6. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
11. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
12. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
[No Abstract] [Full Text] [Related]
13. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer.
Coan M; Rampioni Vinciguerra GL; Cesaratto L; Gardenal E; Bianchet R; Dassi E; Vecchione A; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149579
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
15. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk A; George J; Wang C; Budden T; Tan TZ; Chiu DS; Kommoss S; Leong HS; Chen S; Intermaggio MP; Gilks B; Nazeran TM; Volchek M; Elatre W; Bentley RC; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; Leong SCY; Liu G; Johnson D; Chen B; Group A; Alsop J; Banerjee SN; Behrens S; Bodelon C; Brand AH; Brinton L; Carney ME; Chiew YE; Cushing-Haugen KL; Cybulski C; Ennis D; Fereday S; Fortner RT; García-Donas J; Gentry-Maharaj A; Glasspool R; Goranova T; Greene CS; Haluska P; Harris HR; Hendley J; Hernandez BY; Herpel E; Jimenez-Linan M; Karpinskyj C; Kaufmann SH; Keeney GL; Kennedy CJ; Köbel M; Koziak JM; Larson MC; Lester J; Lewsley LA; Lissowska J; Lubiński J; Luk H; Macintyre G; Mahner S; McNeish IA; Menkiszak J; Nevins N; Osorio A; Oszurek O; Palacios J; Hinsley S; Pearce CL; Pike MC; Piskorz AM; Ray-Coquard I; Rhenius V; Rodriguez-Antona C; Sharma R; Sherman ME; De Silva D; Singh N; Sinn P; Slamon D; Song H; Steed H; Stronach EA; Thompson PJ; Tołoczko A; Trabert B; Traficante N; Tseng CC; Widschwendter M; Wilkens LR; Winham SJ; Winterhoff B; Beeghly-Fadiel A; Benitez J; Berchuck A; Brenton JD; Brown R; Chang-Claude J; Chenevix-Trench G; deFazio A; Fasching PA; García MJ; Gayther SA; Goodman MT; Gronwald J; Henderson MJ; Karlan BY; Kelemen LE; Menon U; Orsulic S; Pharoah PDP; Wentzensen N; Wu AH; Schildkraut JM; Rossing MA; Konecny GE; Huntsman DG; Huang RY; Goode EL; Ramus SJ; Doherty JA; Bowtell DD; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5411-5423. PubMed ID: 32554541
[TBL] [Abstract][Full Text] [Related]
17. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
18. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
[TBL] [Abstract][Full Text] [Related]
19. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes.
Way GP; Rudd J; Wang C; Hamidi H; Fridley BL; Konecny GE; Goode EL; Greene CS; Doherty JA
G3 (Bethesda); 2016 Dec; 6(12):4097-4103. PubMed ID: 27729437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
